Arvinas (ARVN) Share-based Compensation (2017 - 2026)
Arvinas (ARVN) recorded quarterly Share-based Compensation of $12.1 million in Q1 2026, up 42.35% quarter-over-quarter from $8.5 million in Q4 2025, and down 19.33% on a YoY basis from $15.0 million in Q1 2025.
Arvinas (ARVN) Share-based Compensation (2017 - 2026) Analysis & Trends
Arvinas' Share-based Compensation history runs 10 years deep, the most recent figure standing at $12.1 million for Q1 2026.
- In Q1 2026, Share-based Compensation fell 19.33% year-over-year to $12.1 million; the TTM figure through Mar 2026 stood at $41.1 million (down 51.42% YoY), while the FY2025 annual figure was $44.0 million, down 50.11% from the prior year.
- Share-based Compensation was $12.1 million for Q1 2026 at Arvinas, up from $8.5 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $24.7 million in Q3 2024 to a low of $8.5 million in Q4 2025.
- Historically, Share-based Compensation has averaged $17.1 million across 5 years, with a median of $18.3 million in 2023.
- The sharpest annual moves came in 2022 and 2025: Share-based Compensation jumped 61.17% in 2022, then sank 63.52% in 2025.
- A 5-year view of Share-based Compensation shows it stood at $20.1 million in 2022, then fell by 16.92% to $16.7 million in 2023, then surged by 39.52% to $23.3 million in 2024, then tumbled by 63.52% to $8.5 million in 2025, then soared by 42.35% to $12.1 million in 2026.
- The last three Share-based Compensation figures came in at $12.1 million (Q1 2026), $8.5 million (Q4 2025), and $10.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - | 12.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.10 Mn |
| Mar 31, 2026 | 12.10 Mn |
| Dec 31, 2025 | 8.50 Mn |
| Dec 31, 2025 | 8.50 Mn |
| Sep 30, 2025 | 10.20 Mn |
| Sep 30, 2025 | 10.20 Mn |
| Jun 30, 2025 | 10.30 Mn |
| Jun 30, 2025 | 10.30 Mn |
| Mar 31, 2025 | 15.00 Mn |
| Mar 31, 2025 | 15.00 Mn |
| Dec 31, 2024 | 23.30 Mn |
| Dec 31, 2024 | 23.30 Mn |
| Sep 30, 2024 | 24.70 Mn |
| Sep 30, 2024 | 24.70 Mn |
| Jun 30, 2024 | 21.60 Mn |
| Jun 30, 2024 | 21.60 Mn |
| Mar 31, 2024 | 18.60 Mn |
| Mar 31, 2024 | 18.60 Mn |
| Dec 31, 2023 | 16.70 Mn |
| Dec 31, 2023 | 16.70 Mn |